Lingua: Inglese
Editore: Carnegie-Mellon University Press, 1996
ISBN 10: 0887482015 ISBN 13: 9780887482014
Da: 3Brothers Bookstore, Egg harbor township, NJ, U.S.A.
Condizione: good. Books may contain some notes and highlighting. Supplements such as Access Codes, Cd's Dust Jackets, etc. are not guaranteed with used book purchases.
paperback. Condizione: Fine.
paperback. Condizione: Very Good.
Lingua: Inglese
Editore: Carnegie-Mellon University Press, 1996
ISBN 10: 0887482015 ISBN 13: 9780887482014
Da: Equipment for Living, Aliquippa, PA, U.S.A.
Condizione: new.
Da: PBShop.store US, Wood Dale, IL, U.S.A.
PAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000.
Da: PBShop.store UK, Fairford, GLOS, Regno Unito
EUR 40,35
Quantità: 1 disponibili
Aggiungi al carrelloPAP. Condizione: New. New Book. Shipped from UK. Established seller since 2000.
Da: THE SAINT BOOKSTORE, Southport, Regno Unito
EUR 49,40
Quantità: 1 disponibili
Aggiungi al carrelloPaperback / softback. Condizione: New. New copy - Usually dispatched within 4 working days.
Lingua: Inglese
Editore: National Academies Press Nov 2024, 2024
ISBN 10: 0309726557 ISBN 13: 9780309726559
Da: Rheinberg-Buch Andreas Meier eK, Bergisch Gladbach, Germania
EUR 52,00
Quantità: 1 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. Neuware -Rare diseases, such as sickle cell disease and thalassemia, affect up to 30 million people in the United States and at least 300 million across the globe. Congress called on the U.S. Food and Drug Administration (FDA) to sponsor a National Academies study on processes for evaluating the safety and efficacy of drugs for rare diseases or conditions in the United States and the European Union. The resulting report provides recommendations for enhancing and promoting rare disease drug development by improving engagement with people affected by a rare disease, advancing regulatory science, and fostering collaboration between FDA and the European Medicines Agency.
Lingua: Inglese
Editore: National Academies Press Nov 2024, 2024
ISBN 10: 0309726557 ISBN 13: 9780309726559
Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germania
EUR 52,00
Quantità: 1 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. Neuware -Rare diseases, such as sickle cell disease and thalassemia, affect up to 30 million people in the United States and at least 300 million across the globe. Congress called on the U.S. Food and Drug Administration (FDA) to sponsor a National Academies study on processes for evaluating the safety and efficacy of drugs for rare diseases or conditions in the United States and the European Union. The resulting report provides recommendations for enhancing and promoting rare disease drug development by improving engagement with people affected by a rare disease, advancing regulatory science, and fostering collaboration between FDA and the European Medicines Agency.
Da: Revaluation Books, Exeter, Regno Unito
EUR 71,37
Quantità: 1 disponibili
Aggiungi al carrelloPaperback. Condizione: Brand New. 1st edition. 363 pages. 8.75x6.00x1.00 inches. In Stock.
Lingua: Inglese
Editore: National Academies Press Nov 2024, 2024
ISBN 10: 0309726557 ISBN 13: 9780309726559
Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germania
EUR 52,00
Quantità: 1 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. Neuware -Rare diseases, such as sickle cell disease and thalassemia, affect up to 30 million people in the United States and at least 300 million across the globe. Congress called on the U.S. Food and Drug Administration (FDA) to sponsor a National Academies study on processes for evaluating the safety and efficacy of drugs for rare diseases or conditions in the United States and the European Union. The resulting report provides recommendations for enhancing and promoting rare disease drug development by improving engagement with people affected by a rare disease, advancing regulatory science, and fostering collaboration between FDA and the European Medicines Agency.Libri GmbH, Europaallee 1, 36244 Bad Hersfeld.
Lingua: Inglese
Editore: National Academies Press Nov 2024, 2024
ISBN 10: 0309726557 ISBN 13: 9780309726559
Da: AHA-BUCH GmbH, Einbeck, Germania
EUR 52,00
Quantità: 1 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. Neuware - Rare diseases, such as sickle cell disease and thalassemia, affect up to 30 million people in the United States and at least 300 million across the globe. Congress called on the U.S. Food and Drug Administration (FDA) to sponsor a National Academies study on processes for evaluating the safety and efficacy of drugs for rare diseases or conditions in the United States and the European Union. The resulting report provides recommendations for enhancing and promoting rare disease drug development by improving engagement with people affected by a rare disease, advancing regulatory science, and fostering collaboration between FDA and the European Medicines Agency.